Harvard University and Deerfield Management’s Research Partnership

Goodwin advised Harvard University on the transaction

Harvard University established a strategic R&D alliance with Deerfield Management to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield has committed an unprecedented $100 million in initial funding to support the alliance. Spearheaded by Harvard Office of Technology Development, the alliance is expected to catalyze the development of novel therapeutics and rapidly drive innovations toward clinical validation.

A private company wholly owned by affiliates of Deerfield, Lab1636 will support Harvard R&D projects throughout various stages of drug discovery and development, for example enabling studies to explicate the biology of disease, validate therapeutic targets, or achieve a proof-of-concept necessary for filing an Investigational New Drug application.

Harvard’s Office of Technology Development (OTD) promotes the public good by fostering innovation and translating new inventions made at Harvard University into useful products that are available and beneficial to society.

Goodwin advised harward University with a team led by partner Richard Hoffman (Picture), with support from partner Daniel Karelitz and associates Alex Plaum and Brett Jackson.

Involved fees earner: Richard Hoffman – Goodwin Procter; Brett Jackson – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Alexander Plaum – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Harvard University;


Author: Ambrogio Visconti